Indeed, prior small-scale clinical studies in hospitalized infected patients have assessed the accuracy of using elevated levels of biomarkers such as the inflammatory coagulation biomarkers—D-dimer and C-reactive protein (CRP)—in predicting COVID-19 prognosis and mortality risk [12, 13]. This evidence concerns the gene CRP and COVID-19.